Ifetroban pills for idiopathic pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This trial studies ifetroban, an oral medicine, in people with idiopathic pulmonary fibrosis (IPF) to see if it improves outcomes and is safe. It may be an option if your IPF is confirmed on lung scans and your lung function tests meet the trial thresholds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 40 or older
- You have a confirmed IPF diagnosis, such as a “UIP” or “probable UIP” pattern on a recent chest CT (or a prior biopsy that fits
- Your lung function tests are within range: FVC at least 40% predicted, and DLCO between 25% and under 80% predicted
- If you take IPF medicines (pirfenidone or nintedanib), your dose is stable and you plan to keep it stable; you can’t take both together
- You can’t have major recent lung problems like an IPF flare in the last 6 weeks or a chest infection needing antibiotics in the last 4 weeks
- Blood tests and major health conditions (liver, kidneys, bleeding risk, heart problems, and certain blood clot/stroke history) must meet safety limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medicine called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to see if the drug can help slow the disease. You may qualify if you are 40 or older, have a confirmed IPF diagnosis with certain lung function levels, and are either on a stable dose of standard IPF meds or not taking them.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
This study tests whether a new tablet called SYH2059 can help slow lung scarring in adults with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes thick and stiff over time. You'll take the study drug alongside your current lung treatment to see if it improves your breathing and lung function.
This trial tests an experimental drug called MTX-463 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if targeting a protein called WISP1 can slow lung scarring and help you breathe better.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.